EEF1A2 and prostate carcinoma: The sTn antigen is being widely investigated as a circulating biomarker for other cancers [62,63], and it is likely that innovative tools that were developed to detect sTn [63,64,65] will also have clinical utility for prostate cancer precision oncology.